Safe and effective use of imatinib to treat Philadelphia chromosome positive acute lymphoblastic leukemia during pregnancy

Authors

Sarah Ashraf, Aga Khan University
Julie Wolfson, University of Alabama at Birmingham, Alabama, USA
Pankit Vachhani, Department of Medicine, University of Alabama at Birmingham, USA
Sravanti Rangaraju, Department of Medicine, University of Alabama at Birmingham, USA
Kimo Bachiashvili, Department of Medicine, University of Alabama at Birmingham, USA
Ravi Bhatia, Department of Medicine, University of Alabama at Birmingham, USA
Omer Jamy, Department of Medicine, University of Alabama at Birmingham, USA

Document Type

Article

Department

Medical College Pakistan

Abstract

Philadelphia chromosome positive (Ph+) B cell acute lymphoblastic leukemia (ALL) is extremely rare in pregnancy. Although the use of tyrosine kinase inhibitors (TKIs) has significantly improved outcomes of patients with Ph+ ALL, its use during pregnancy is not recommended due to the risk of fetal malformations. There are limited data on the use of TKIs during pregnancy and its long-term effects on the fetus. Within this context, we present a case of a 25-year-old woman diagnosed with Ph+ ALL during the third trimester and the safe and effective use of imatinib as treatment after failure of conventional chemotherapy.

Comments

Volume, issue, and pagination are not provided by the author/publisher

Publication (Name of Journal)

Journal of adolescent and young adult oncology

Recommended Citation

Ashraf, S., Wolfson, J., Vachhani, P., Rangaraju, S., Bachiashvili, K., Bhatia, R., Jamy, O. (2022). Safe and effective use of imatinib to treat Philadelphia chromosome positive acute lymphoblastic leukemia during pregnancy. Journal of adolescent and young adult oncology.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_mc/247